Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

(2016) Joanne P. Lagmay et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome for adolescent and young adult patients with osteosarcoma

(2012) Katherine A. Janeway et al.   CANCER

Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003

(2012) E. Fox et al.   ONCOLOGIST

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study

(2012) Anne B. Warwick et al.   PEDIATRIC BLOOD & CANCER

Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

(2010) S. Jacobs et al.   CLINICAL CANCER RESEARCH

Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects

(2010) Katherine A Janeway et al.   LANCET ONCOLOGY

A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study

(2010) Orren Beaty et al.   PEDIATRIC BLOOD & CANCER

Osteosarcoma incidence and survival rates from 1973 to 2004

(2009) Lisa Mirabello et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

(2008) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS